# Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01294436` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01294436](<https://clinicaltrials.gov/study/NCT01294436>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01294436

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 728 participants.

## Technical summary

Registry record NCT01294436. Allocation not applicable; no masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2013-09-16.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 728 participants (enrolled count; ClinicalTrials.gov record NCT01294436, source copy `cardio:ctgov-nct01294436-2013-12-17`, retrieved 2026-10-26)
- Start date: 2011-02 (registry gives no type) (ClinicalTrials.gov record NCT01294436, source copy `cardio:ctgov-nct01294436-2013-12-17`, retrieved 2026-10-26)
- Primary completion: 2012-09 (actual) (ClinicalTrials.gov record NCT01294436, source copy `cardio:ctgov-nct01294436-2013-12-17`, retrieved 2026-10-26)
- Completion: 2012-09 (actual) (ClinicalTrials.gov record NCT01294436, source copy `cardio:ctgov-nct01294436-2013-12-17`, retrieved 2026-10-26)
- Results first posted: 2013-09-16 (ClinicalTrials.gov record NCT01294436, source copy `cardio:ctgov-nct01294436-2013-12-17`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01294436, source copy `cardio:ctgov-nct01294436-2013-12-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01294436-2013-12-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
- Condition: Type2 Diabetes
- Condition: High Blood Sugar
- Intervention (Drug): Dapagliflozin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

## Provenance

Content hash: d85ebb33124034592d3db826a0d6879a21a74e9d723cd552e455c138b24f03ac
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
